TY - JOUR
T1 - The pharmacological management of skeletal-related events from metastatic tumors
AU - Hitron, Anna
AU - Adams, Val
N1 - Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2009/3
Y1 - 2009/3
N2 - Since the mid-1990s, bisphosphonates have become a mainstay of the management of metastatic bone disease from breast, lung, and prostate cancer. They are the primary treatment of hypercalcemia, widely recommended to reduce the pain associated with metastatic disease and are the only class of agents approved to prevent the development of skeletal-related events. Copyright ® 2009 SLACK Incorporated. All rights reserved.
AB - Since the mid-1990s, bisphosphonates have become a mainstay of the management of metastatic bone disease from breast, lung, and prostate cancer. They are the primary treatment of hypercalcemia, widely recommended to reduce the pain associated with metastatic disease and are the only class of agents approved to prevent the development of skeletal-related events. Copyright ® 2009 SLACK Incorporated. All rights reserved.
UR - http://www.scopus.com/inward/record.url?scp=65649153708&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=65649153708&partnerID=8YFLogxK
U2 - 10.3928/01477447-20090301-13
DO - 10.3928/01477447-20090301-13
M3 - Article
C2 - 19309055
AN - SCOPUS:65649153708
SN - 0147-7447
VL - 32
SP - 188
JO - Orthopedics
JF - Orthopedics
IS - 3
ER -
